Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $76.17

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have covered the stock in the last year is $76.17.

A number of analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. Citigroup assumed coverage on Structure Therapeutics in a research report on Friday, May 2nd. They set a “buy” rating and a $60.00 price objective for the company. HC Wainwright reduced their price objective on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Monday, May 12th. Finally, JMP Securities reiterated a “market outperform” rating and set a $89.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $20.62 on Thursday. The company has a market cap of $1.18 billion, a P/E ratio of -23.70 and a beta of -1.87. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $47.48. The stock’s fifty day moving average price is $23.15 and its 200-day moving average price is $23.43.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). On average, sell-side analysts anticipate that Structure Therapeutics will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Jones Financial Companies Lllp boosted its stake in Structure Therapeutics by 29.8% during the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock valued at $115,000 after buying an additional 971 shares during the last quarter. Assetmark Inc. raised its holdings in shares of Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock worth $62,000 after buying an additional 953 shares during the period. M&T Bank Corp raised its holdings in shares of Structure Therapeutics by 100.0% in the fourth quarter. M&T Bank Corp now owns 18,110 shares of the company’s stock worth $492,000 after buying an additional 9,055 shares during the period. Candriam S.C.A. raised its holdings in shares of Structure Therapeutics by 59.6% in the fourth quarter. Candriam S.C.A. now owns 215,421 shares of the company’s stock worth $5,842,000 after buying an additional 80,421 shares during the period. Finally, Vestcor Inc purchased a new stake in shares of Structure Therapeutics in the fourth quarter worth approximately $127,000. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.